Streetbeat News

TRCK

Track Group Inc

Employees

154

Industry

Other Communications Equipment Manufacturing

Open

0.08

Mkt cap

830K

Volume

High

0.08

P/E Ratio

-0.20

52-wk high

0.42

Low

0.07

Div yield

N/A

52-wk low

0.01

Lipocine Inc. has received Fast Track Designation from the FDA for LPCN 1148, a treatment for sarcopenia in patients with decompensated cirrhosis. This designation could expedite the development and review process for the drug.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

Data Journey has announced the purchase of a property in Spartanburg, South Carolina, from Greenidge Generation for $12.1 million. This acquisition marks Data Journey's entry into the South Carolina market and aligns with their aggressive growth strategy.

Portfolio Pulse from

December 12, 2024 | 7:30 pm

The FDA has granted Fast Track designation to Sanofi's two combination vaccine candidates aimed at preventing influenza and COVID-19 infections. This designation is intended to expedite the development and review process of these vaccines.

Portfolio Pulse from

December 11, 2024 | 4:45 pm

Sanofi's two combination vaccine candidates for influenza and COVID-19 have received Fast Track designation from the US FDA. These are the first non-mRNA combination vaccines, and ongoing phase 1/2 studies are evaluating their safety and immune response.

Portfolio Pulse from

December 11, 2024 | 6:15 am

Descartes Systems reported strong Q3'25 results with 15% revenue growth and 14% adjusted EBITDA growth, driven by successful M&A activities. The company completed five acquisitions in fiscal 2025, enhancing capabilities in various sectors. Descartes' focus on innovation and AI, along with a debt-free balance sheet, positions it for sustained growth.

Portfolio Pulse from

December 05, 2024 | 5:45 pm

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has received Fast Track designation from the FDA for its drug CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer. This designation could expedite the development and review process for CRB-701.

Portfolio Pulse from

December 03, 2024 | 12:15 pm

Rigel Pharmaceuticals announced that the FDA has granted Fast Track designation to its drug R289 for treating lower-risk myelodysplastic syndrome. This designation could expedite the drug's development and review process.

Portfolio Pulse from

December 02, 2024 | 1:30 pm

Inter & Co is on track with its ambitious 2027 plan, aiming for 60 million customers, a 30% efficiency ratio, and a 30% ROE. The company has made significant progress, reducing its efficiency ratio from 75% to 50.7% in two years.

Portfolio Pulse from

November 28, 2024 | 10:00 am

The article discusses the potential for generative AI revenue to increase tenfold by 2030, suggesting that while investor excitement for AI might be overhyped, there are specific stocks that could benefit significantly. The article hints at a particular AI stock, TRCK, that may benefit from this growth, rather than the commonly mentioned Nvidia.

Portfolio Pulse from

November 24, 2024 | 8:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.